Page 281 - Read Online

Dello Russo et al. Neuroimmunol Neuroinflammation 2018;5:36 I http://dx.doi.org/10.20517/2347-8659.2018.42 Page 13 of 13

tiate antiglioma immunity. Clin Cancer Res 2011;17:771-82.
80. Zhang F, Mastorakos P, Mishra MK, Mangraviti A, Hwang L, Zhou J, Hanes J, Brem H, Olivi A, Tyler B, Kannan RM. Uniform brain
tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. Biomaterials 2015;52:507-16.
81. Osterberg N, Ferrara N, Vacher J, Gaedicke S, Niedermann G, Weyerbrock A, Doostkam S, Schaefer HE, Plate KH, Machein MR. De-
crease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. Neuro Oncol
2016;18:939-49.
82. Miyauchi JT, Chen D, Choi M, Nissen JC, Shroyer KR, Djordevic S, Zachary IC, Selwood D, Tsirka SE. Ablation of Neuropilin 1 from
glioma-associated microglia and macrophages slows tumor progression. Oncotarget 2016;7:9801-14.
83. Juratli TA, Schackert G, Krex D. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Pharmacol Ther 2013;139:341-58.
84. van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for
effective glioblastoma treatment. Drug Resist Updat 2015;19:1-12.